Status:
UNKNOWN
Proteomic Characterization of Aggressive Oligodendrogliomas
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Oligodendroglioma
Eligibility:
All Genders
Brief Summary
Oligodendrogliomas represent a distinct subgroup of adult gliomas characterized by specific molecular alterations (1p/19q codeletion, mutations of IDH, TERT promoter, CIC, FUBP1). These tumors account...
Eligibility Criteria
Inclusion
- \- transcriptomic (microarray) data available or possible to obtain them,
- methylation (450K) data available or possible to obtain them,
- genomic (SNP array) data available or possible to obtain them,
- sufficient material for proteomic analysis (frozen tumor samples)
Exclusion
- opposed patients
Key Trial Info
Start Date :
September 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04843085
Start Date
September 30 2020
End Date
September 1 2023
Last Update
April 13 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Groupement Hospitalier Est HCL
Bron, France
2
Institut du Cerveau et de la Moelle
Paris, France